HLTRF - HLS Therapeutics GAAP EPS of -$0.13 revenue of $15.7M misses by $0.93M March, 17 2022 06:38 AM HLS Therapeutics Inc HLS Therapeutics press release (OTCPK:HLTRF): Q4 GAAP EPS of -$0.13. Revenue of $15.7M (-4.8% Y/Y) misses by $0.93M. For further details see: HLS Therapeutics GAAP EPS of -$0.13, revenue of $15.7M misses by $0.93M